Published in Lancet Oncol on February 01, 2007
Thermal Ablation of Cervical Metastases From Thyroid Carcinoma | NCT04522570
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol (2010) 3.75
Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 2.67
Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol (2008) 2.58
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res (2010) 2.44
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res (2011) 1.47
Concern Spinal metastasis in thyroid cancer. Head Neck Oncol (2012) 1.20
SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med (2012) 1.18
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta (2009) 1.18
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab (2009) 1.13
Spinal cord compression as initial presentation of metastatic occult follicular thyroid carcinoma. J Neurosci Rural Pract (2014) 1.00
Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist (2010) 1.00
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget (2010) 0.98
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis (2014) 0.96
New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 0.94
Identification of a recurrent STRN/ALK fusion in thyroid carcinomas. PLoS One (2014) 0.93
Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med (2013) 0.92
Imaging for staging and management of thyroid cancer. Cancer Imaging (2008) 0.89
Thyroid cancer: current molecular perspectives. J Oncol (2010) 0.87
Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer (2015) 0.85
Multi-targeted approach in the treatment of thyroid cancer. Minerva Chir (2010) 0.85
Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging (2013) 0.85
Molecular Targeted Therapies of Aggressive Thyroid Cancer. Front Endocrinol (Lausanne) (2015) 0.85
A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol (2015) 0.83
MicroRNA expression profiles in the management of papillary thyroid cancer. Oncologist (2014) 0.83
Targeted radionuclide therapy. Cancers (Basel) (2011) 0.83
Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg (2010) 0.82
Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells. J Exp Clin Cancer Res (2015) 0.80
A case report of "spinal cord apoplexy" elicited by metastatic intramedullary thyroid carcinoma. J Korean Neurosurg Soc (2012) 0.79
Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments. J Thyroid Res (2015) 0.77
The Importance of Caveolin-1 as Key-Regulator of Three-Dimensional Growth in Thyroid Cancer Cells Cultured under Real and Simulated Microgravity Conditions. Int J Mol Sci (2015) 0.77
Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma. BMC Genomics (2015) 0.76
Induction of atypical cell death in thyroid carcinoma cells by the indirubin derivative 7-bromoindirubin-3'-oxime (7BIO). Cancer Cell Int (2015) 0.75
MicroRNAs in the thyroid. Best Pract Res Clin Endocrinol Metab (2016) 0.75
Thyroid computed tomography imaging: pictorial review of variable pathologies. Insights Imaging (2016) 0.75
A 'silent' skull metastatic follicular thyroid carcinoma mimicking as a benign scalp tumor in a pregnant woman. Endocrinol Diabetes Metab Case Rep (2017) 0.75
Transient partial response of poorly-differentiated thyroid carcinoma to sunitinib treatment: A case report. Oncol Lett (2015) 0.75
The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells. Cancer Cell Int (2016) 0.75
Management of differentiated thyroid carcinoma with bone metastasis: a case report and review of the Chinese literature. J Zhejiang Univ Sci B (2014) 0.75
Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther (2015) 0.75
Intramedullary spinal cord metastasis arising from papillary thyroid carcinoma: A case report and review of literature. Surg Neurol Int (2016) 0.75
Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells. Oncotarget (2017) 0.75
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57
Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol (2010) 3.11
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med (2008) 2.47
Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44
Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg (2012) 2.35
Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab (2008) 2.30
Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol (2008) 2.23
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol (2008) 2.23
Assessment of the cost of fine-needle aspiration cytology as a diagnostic tool in patients with thyroid nodules. Am J Clin Pathol (2008) 2.18
Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab (2007) 2.06
Management of retropharyngeal node metastases from thyroid carcinoma. World J Surg (2015) 1.98
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Dual oxidase2 is expressed all along the digestive tract. Am J Physiol Gastrointest Liver Physiol (2004) 1.84
Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol (2002) 1.81
Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab (2007) 1.72
Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab (2005) 1.64
Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage. J Infect Dis (2002) 1.57
Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol (2002) 1.51
Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49
Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol (2005) 1.46
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab (2006) 1.45
Medullary thyroid carcinoma. Clin Endocrinol (Oxf) (2004) 1.42
Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: a retrospective cohort study. Lancet Oncol (2012) 1.41
Ernest L. Mazzaferri, MD, MACP (1936-2013). Thyroid (2013) 1.39
Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One (2011) 1.39
Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer (2013) 1.31
Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol (2013) 1.31
Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab (2006) 1.30
Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab (2005) 1.30
Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer (2002) 1.28
Intracellular expression of reactive oxygen species-generating NADPH oxidase NOX4 in normal and cancer thyroid tissues. Endocr Relat Cancer (2010) 1.20
Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol (2005) 1.18
131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med (2008) 1.17
Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab (2003) 1.17
Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol (2008) 1.17
Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab (2007) 1.16
Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.15
Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid (2002) 1.13
Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. J Clin Endocrinol Metab (2002) 1.11
Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol (2005) 1.09
Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancer. Lancet Oncol (2009) 1.09
High rate of multifocality and occult lymph node metastases in papillary thyroid carcinoma arising in thyroglossal duct cysts. Ann Surg Oncol (2009) 1.08
MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol (2003) 1.07
Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab (2013) 1.05
Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery (2003) 1.05
Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab (2009) 1.03
Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab (2011) 1.01
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer (2009) 1.01
Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol (2003) 1.01
Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol (2005) 0.99
Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther (2012) 0.99
Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models. Clin Cancer Res (2011) 0.98
Influence of prophylactic neck dissection on rate of retreatment for papillary thyroid carcinoma. World J Surg (2013) 0.98
Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol (2011) 0.98
Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid (2007) 0.97
[Potential radiation hazard in nuclear medicine]. Rev Prat (2015) 0.97
Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-mediated tumor apoptotic switch. J Clin Invest (2007) 0.97
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther (2013) 0.96
Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells. Cancer Res (2010) 0.96
Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid (2002) 0.95
Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology (2010) 0.95
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol (2012) 0.94
PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. Eur J Endocrinol (2004) 0.92
Is (18)F-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid (2012) 0.91
Functional consequences of dual oxidase-thyroperoxidase interaction at the plasma membrane. J Clin Endocrinol Metab (2010) 0.91
The risk of multiple primary breast and thyroid carcinomas. Cancer (2003) 0.91
18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging (2010) 0.91
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer (2014) 0.90
Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence. Ann Surg Oncol (2009) 0.89
Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol Metab (2011) 0.89
Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy. Eur J Radiol (2007) 0.89
Expression of cell cycle biomarkers and telomere length in papillary thyroid carcinoma: a comparative study between radiation-associated and spontaneous cancers. Am J Clin Oncol (2009) 0.88
Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. Cancer (2007) 0.88
[Evaluation of the lifetime of nail markings during polio vaccinations in Chad]. Sante (2010) 0.88
High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol (2011) 0.88
Expression of the apical iodide transporter in human thyroid tissues: a comparison study with other iodide transporters. J Clin Endocrinol Metab (2004) 0.88
Clinical review: Current concepts in the management of unilateral recurrent laryngeal nerve paralysis after thyroid surgery. J Clin Endocrinol Metab (2005) 0.87
Gene expression signature discriminates sporadic from post-radiotherapy-induced thyroid tumors. Endocr Relat Cancer (2011) 0.87
Menstrual and reproductive factors in the risk of differentiated thyroid carcinoma in young women in France: a population-based case-control study. Am J Epidemiol (2014) 0.86
Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab (2011) 0.86
Age-dependent variation of follicular size and expression of iodine transporters in human thyroid tissue. J Nucl Med (2004) 0.85
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol (2014) 0.85
FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer (2011) 0.84
One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2013) 0.84
Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging (2002) 0.84
Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab (2002) 0.83
Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J Clin Endocrinol Metab (2013) 0.83
Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways. Endocr Relat Cancer (2009) 0.83
Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma. Am J Clin Oncol (2010) 0.83
Hes1 is required for appropriate morphogenesis and differentiation during mouse thyroid gland development. PLoS One (2011) 0.83
Thyroid adenomas after solid cancer in childhood. Int J Radiat Oncol Biol Phys (2012) 0.83
Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy. Radiother Oncol (2009) 0.83
Serum thyroglobulin determination in thyroid cancer patients. Best Pract Res Clin Endocrinol Metab (2008) 0.83
Sodium/iodide symporter (NIS) gene expression is the limiting step for the onset of thyroid function in the human fetus. J Clin Endocrinol Metab (2006) 0.82